CompletedPhase 3

Evaluation of Long-Term Sequelae After Thrombophlebitis, i.e. Deep Venous Thrombosis of the Lower Extremities

Denmark99 participantsStarted 1993-10

Plain-language summary

The purpose of the study was to evaluate efficacy and safety of the new acute treatment of deep venous thrombosis by use of low-molecular-weight heparin compared with standard treatment using unfractionated heparin, especially concerning long-term morbidity.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * First DVT with or without known risk factors except overt cancer * Second DVT more than two years after the first if the patient was without clinical signs of CVI. Exclusion Criteria: * Contraindication to anticoagulation therapy * Candidate to thrombectomy with arterious-venous fistula or thrombolytic therapy * Known cancer at the time of the DVT diagnosis * Patients unable to cooperate for anticoagulation therapy or manage the tests.

What they're measuring

Clinical evaluation of chronic venous insufficiency (CVI) - (Postthrombotic Syndrome) based on internationally accepted criteria.

Timeframe: Two years and 6 to 10 years

Trial details

NCT IDNCT00628576

SponsorAalborg University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2004-06

View on ClinicalTrials.gov More Deep Venous Thrombosis trials